Clinical trial / 2009
Co-administration of chlorophyll or chlorophyllin impeded aflatoxin B1 absorption and lowered Cmax and AUC in human volunteers.
An unblinded crossover study evaluated the pharmacokinetics of a microdose of 14C-AFB(1) (30 ng) alone or co-administered with 150 mg of purified chlorophyll (Chla) or chlorophyllin (CHL) across three protocols repeated thrice in human volunteers. Fasted AFB(1) alone showed rapid uptake with plasma k(a) of 5.05 ± 1.10 h(-1), T(max) of 1.0 hour, and 95% complete urinary elimination by 24 hours. Co-treatment with Chla or CHL significantly impeded AFB(1) absorption and reduced Cmax and AUCs in plasma and urine in one or more subjects.
- Study type
- Unblinded crossover trial
- Who was studied
- 4 human volunteers (3 participated in cotreatment protocols)
- What was measured
- 14C-AFB(1) pharmacokinetics including absorption, elimination, Cmax, and AUC
THE PAPER
Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B(1) pharmacokinetics in human volunteers.
Jubert C, Mata J, Bench G, Dashwood R, Pereira C, Tracewell W, Turteltaub K, Williams D, Bailey G. Cancer Prev Res (Phila), 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.